AGENNIX INCORPORATED NEWS

07/01/2008
Results Published in the Journal Cancer Demonstrate That Oral Talactoferrin Alfa Is Active As Monotherapy In Previously Treated Patients With Metastatic Renal Cell Carcinom


04/22/2008
Agennix Initiates a Randomized Double-Blind, Placebo-Controlled Phase 2 Study Of Oral Talactoferrin in Severe Sepsis

Company also announces Award of a National Institutes of Health Small Business Innovative Research (SBIR) Grant to support the Phase 2 Trial


02/26/2008
Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at The 8th Annual Targeted Therapies For The Treatment Of Lung Cancer Meeting

Company Also Announces Receipt of Fast Track Designation from FDA, Favorable Scientific Advice from EMEA and Phase 3 Plans for the Non-Small Cell Lung Cancer Monotherapy Indication


01/17/2008
Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer

Trial will also Support a Marketing Authorization Application in the European Union


06/04/2007
Survival Benefit Demonstrated in Placebo-Controlled Trial in Patients With Refractory Non-Small Cell Lung Cancer Treated With Agennix's Oral Talactoferrin

Data from the Randomized, Double-Blind, Placebo-Controlled Phase II Trial Presented at ASCO


10/12/2006
Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma


10/05/2006
Agennix Receives FDA Fast Track Designation for Talactoferrin Alfa in Non-Small Cell Lung Cancer and Diabetic Foot Ulcer


06/14/2005
Biopharma Agennix To Seek Up To $50M For Phase III Trials


06/13/2005
Agennix's Topical Talactoferrin Improved Healing of Diabetic Ulcers


05/17/2005
Agennix's Oral Talactoferrin Improved Response Rates, Time to Progression and Duration of Response When Combined with First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer Presented at AAdvanced Non-Small Cell Lung Cancer


04/19/2005
Agennix's Oral Talactoferrin Substantially Improved Response Rates When Combined with First-Line Chemotherapy in Advanced Non-Small Cell Lung Caner


03/30/2005
Agennix Raises $22 Million in Private Financing


08/18/2004
Agennix Data Published in the International Journal of Cancer


06/09/2004
VAMC and Agennix Release Lactoferrin Cancer Trial Results at ASCO


05/25/2004
Agennix Receives SBIR Asthma Funding, Presents at ATS Meeting


03/30/2004
Agennix Presents Positive RhLF Cancer Results at AACR Meeting


03/09/2004
Agennix Composition of Matter Patent on Recombinant Human Lactoferrin Upheld in Europe


09/17/2003
Agennix Inc. Receives $850,000 NIH Funding to Support Clinical Trials of rhLF Gel for Treatment of Patients with Diabetic Foot Ulcers


06/30/2003
Agennix appoints Dr. Frank Young Chairman of its Board of Directors


06/18/2003
Agennix Inc. Presents Positive Results Showing Accelerated Wound Healing and Wound Closure with Topical Recombinant Human Lactoferrin


05/22/2003
VAMC and Agennix Successfully Complete Safety Phase of Lactoferrin Cancer Trial


09/17/2002
Agennix and DSM Pharmaceutical Products announce opening of recombinant human lactoferrin manufacturing facility


05/29/2002
Agennix Completes $20 Million Private Placement Financing


05/14/2001
Dr. Waun Ki Hong, head of M.D. Anderson's Division of Cancer Medicine joins Agennix's Scientific Advisory


05/10/2001
Agennix Receives Broad Patent Covering Production of Human Lactoferrin in Eukaryotic Cell